Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease

Alzheimer's disease: the amyloid cascade hypothesis

Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

Staging of alzheimer's disease-related neurofibrillary changes

Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357 · see citing works

Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease

HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542 · see citing works

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,488 · see citing works

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · see citing works

Greenfield's Neuropathology

(1964) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1964.tb115841.x · Cited by 1,411 · see citing works

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · see citing works

Tauopathy in <i>Drosophila</i> : Neurodegeneration Without Neurofibrillary Tangles

Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M., & Feany, M. B. (2001) · Science · doi:10.1126/science.1062382 · Cited by 939 · see citing works

Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works

Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship

Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643 · see citing works

Amyloid precursor protein processing and Aβ 42 deposition in a transgenic mouse model of Alzheimer disease

Johnson‐Wood, K., Lee, M., Motter, R. N., Hu, K., Gordon, G., Barbour, R., Khan, K., Gordon, M. N., Tan, H. T., Games, D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1550 · Cited by 634 · see citing works

Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205

Goedert, M., Jakes, R., & Vanmechelen, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11484-e · Cited by 608 · see citing works

Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

Ferrer, I., Boada, M., Guerra, M. L. S., Rey, M. J., & Costa‐Jussà, F. R. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 567 · see citing works

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works

Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy

Berger, Z., Roder, H. M., Hanna, A., Carlson, A. M., Rangachari, V., Yue, M., Wszołek, Z. K., Ashe, K. H., Knight, J. A., Dickson, D. W., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0587-07.2007 · Cited by 485 · see citing works

The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region.

Biernat, J., Mandelkow, E. M., Schröter, C., Lichtenberg‐Kraag, B., Steiner, B., Berling, B., Meyer, H., Mercken, M., Vandermeeren, A., & Goedert, M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05204.x · Cited by 484 · see citing works

Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD

Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356 · see citing works

Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

Masliah, E., Hansen, L., Adame, A., Crews, L. A., Bard, F., Lee, C., Seubert, P. A., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 355 · see citing works

Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain

Boche, D., Zotova, E., Weller, R. O., Love, S., Neal, J. W., Pickering, R. M., Wilkinson, D., Holmes, C., & Nicoll, J. A. R. (2008) · Brain · doi:10.1093/brain/awn261 · Cited by 316 · see citing works

Aβ Species Removal After Aβ ₄₂ Immunization

Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265 · see citing works

Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice

Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190 · see citing works

Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology

Serrano-Pozo, A., William, C. M., Ferrer, I., Uro-Coste, E., Delisle, M.-B., Maurage, C.-A., Hock, C., Nitsch, R. M., Masliah, E., Growdon, J. H., et al. (2010) · Brain · doi:10.1093/brain/awq056 · Cited by 159 · see citing works

Greenfield's Neuropathology

HART, M. N. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181839bfd · Cited by 145 · see citing works

Amyloid Reduction by Amyloid- Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease

Wilcock, D. M., Gharkholonarehe, N., Nostrand, W. E. V., Davis, J., Vitek, M. P., & Colton, C. A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1339-09.2009 · Cited by 97 · see citing works

Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies

Sigurdsson, E. M. (2009) · Current Alzheimer Research · doi:10.2174/156720509789207930 · Cited by 87 · see citing works

Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment

Mitchell, T. W., Nissanov, J., Han, L.-Y., Mufson, E. J., Schneider, J. A., Cochran, E. J., Bennett, D. A., Lee, V. M.-Y., Trojanowski, J. Q., & Arnold, S. E. (2000) · Journal of Histochemistry &amp; Cytochemistry · doi:10.1177/002215540004801206 · Cited by 78 · see citing works

Ageing and dementia

Lowe, J. S., Mirra, S. S., Hyman, B. T., & Dickson, D. W. (2008) · CRC Press eBooks · doi:10.1201/b13319-15 · Cited by 68 · see citing works

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · see citing works

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 697 · see citing works

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis

Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Domı́nguez, L., Shea, J., Dokholyan, N. V., Simone, A. D., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 676 · see citing works

Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522 · see citing works

Tau Aggregation and Its Interplay with Amyloid-β

Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359 · see citing works

Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies

Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0826-y · Cited by 365 · see citing works

Temporal and regional progression of Alzheimer’s disease‐like pathology in 3xTg‐AD mice

Belfiore, R., Rodin, A., Ferreira, E., Velazquez, R., Branca, C., Caccamo, A., & Oddo, S. (2019) · Aging Cell · doi:10.1111/acel.12873 · Cited by 332 · see citing works

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease

Brothers, H. M., Gosztyla, M. L., & Robinson, S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00118 · Cited by 314 · see citing works

Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review

Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306 · see citing works

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272 · see citing works

Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization

Zotova, E., Bharambe, V., Cheaveau, M., Morgan, W., Holmes, C., Harris, S., Neal, J. W., Love, S., Nicoll, J. A. R., & Boche, D. (2013) · Brain · doi:10.1093/brain/awt210 · Cited by 272 · see citing works

Tau Proteins and Tauopathies in Alzheimer’s Disease

Chong, F. P., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0574-1 · Cited by 248 · see citing works

Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease

Nicoll, J. A. R., Buckland, G. R., Harrison, C. H., Page, A. M., Harris, S., Love, S., Neal, J., Holmes, C., & Boche, D. (2019) · Brain · doi:10.1093/brain/awz142 · Cited by 205 · see citing works

Immunotherapy for Alzheimer’s disease: hoops and hurdles

Lemere, C. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-36 · Cited by 196 · see citing works

Alzheimer’s disease: How metal ions define β-amyloid function

Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 151 · see citing works

Neuroinflammatory responses in Alzheimer’s disease

Dansokho, C., & Heneka, M. T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1831-7 · Cited by 143 · see citing works

Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis

Boche, D., Denham, N., Holmes, C., & Nicoll, J. A. R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0719-5 · Cited by 135 · see citing works

Alzheimer’s disease due to loss of function: A new synthesis of the available data

Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 123 · see citing works

Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles

Iqbal, K., Liu, F., & Gong, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.002 · Cited by 110 · see citing works

The effect of insomnia on development of Alzheimer’s disease

Sadeghmousavi, S., Eskian, M., Rahmani, F., & Rezaei, N. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01960-9 · Cited by 113 · see citing works

Plaque-associated local toxicity increases over the clinical course of Alzheimer disease

Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100 · see citing works

Tau as a Therapeutic Target for Alzheimers Disease

Boutajangout, A., Sigurdsson, E. M., & Krishnamurthy, P. K. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717195 · Cited by 97 · see citing works

Open questions for Alzheimer’s disease immunotherapy

Golde, T. E. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt233 · Cited by 85 · see citing works

Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy

Vasilevko, V., Passos, G. F., Quiring, D., Head, E., Kim, R. C., Fisher, M., & Cribbs, D. H. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05786.x · Cited by 72 · see citing works

Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy

Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72 · see citing works

Immunotherapy for Alzheimer’s disease: past, present and future

Spencer, B. J., & Masliah, E. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00114 · Cited by 73 · see citing works

Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy

Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 77 · see citing works

Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias

Jaisa-aad, M., Muñoz-Castro, C., Healey, M. A., Hyman, B., & Serrano-Pozo, A. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02712-2 · Cited by 65 · see citing works

Microglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study

Franco-Bocanegra, D. K., George, B., Lau, L. C., Holmes, C., Nicoll, J. A. R., & Boche, D. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0828-x · Cited by 64 · see citing works

Ursolic and oleanolic acid derivatives with cholinesterase inhibiting potential

Loesche, A., Köwitsch, A., Lucas, S. D., Alhalabi, Z., Sippl, W., Al‐Harrasi, A., & Csük, R. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.12.013 · Cited by 62 · see citing works

Regional differences in Alzheimer’s disease pathology confound behavioural rescue after amyloid-β attenuation

Morrone, C. D., Bazzigaluppi, P., Beckett, T., Hill, M., Koletar, M., Stefanovic, B., & McLaurin, J. (2019) · Brain : a journal of neurology · doi:10.1093/brain/awz371 · Cited by 62 · see citing works

Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?

Checler, F., Afram, E., Pardossi‐Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 61 · see citing works

Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease

Sastre, M., Richardson, J. C., Gentleman, S., & Brooks, D. J. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256062 · Cited by 58 · see citing works

Alzheimer disease neuropathology in a patient previously treated with aducanumab

Plowey, E. D., Bussière, T., Rajagovindan, R., Sebalusky, J., Hamann, S., von Hehn, C., Castrillo‐Viguera, C., Sandrock, A. W., Haeberlein, S. B., van Dyck, C. H., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02433-4 · Cited by 59 · see citing works

Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics

Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 56 · see citing works

Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease

Novak, G., Fox, N. C., Clegg, S., Nielsen, C. F., Einstein, S. G., Lü, Y., Tudor, I. C., Gregg, K. M., Di, J., Collins, P. V., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150448 · Cited by 53 · see citing works

Antibody Therapeutics Targeting Aβ and TauPreprint

Gallardo, G., & Holtzman, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024331 · Cited by 51 · see citing works

Blocking the Apolipoprotein E/Amyloid-β Interaction Reduces Fibrillar Vascular Amyloid Deposition and Cerebral Microhemorrhages in TgSwDI Mice

Yang, J., Ji, Y., Mehta, P. D., Bates, K. A., Sun, Y., & Wısnıewskı, T. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101401 · Cited by 48 · see citing works

Inflammation in Alzheimer’s disease: insights from immunotherapy

Schott, J. M., & Révész, T. (2013) · Brain · doi:10.1093/brain/awt231 · Cited by 50 · see citing works

Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology

Rosenberg, R. N., Fu, M., & Lambracht‐Washington, D. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0441-4 · Cited by 48 · see citing works

A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies

Lathuilière, A., Laversenne, V., Astolfo, A., Kopetzki, E., Jacobsen, H., Stampanoni, M., Bohrmann, B., Schneider, B. L., & Aebischer, P. (2016) · Brain · doi:10.1093/brain/aww036 · Cited by 46 · see citing works

The biochemical aftermath of anti-amyloid immunotherapy

Maarouf, C. L., Daugs, I. D., Kokjohn, T. A., Kalback, W. M., Patton, R., Luehrs, D. C., Masliah, E., Nicoll, J. A. R., Sabbagh, M. N., Beach, T. G., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-39 · Cited by 43 · see citing works

Effect of active A<i>β</i> immunotherapy on neurons in human Alzheimer's disease

Paquet, C., Amin, J., Mouton‐Liger, F., Nasser, M., Love, S., Gray, F., Pickering, R. M., Nicoll, J. A., Holmes, C., Hugon, J., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4491 · Cited by 44 · see citing works

Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials

Boche, D., & Nicoll, J. A. R. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12642 · Cited by 40 · see citing works

Downregulated apoptosis and autophagy after anti‐Aβ immunotherapy in Alzheimer's disease

Paquet, C., Nicoll, J. A. R., Love, S., Mouton‐Liger, F., Holmes, C., Hugon, J., & Boche, D. (2017) · Brain Pathology · doi:10.1111/bpa.12567 · Cited by 40 · see citing works

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease

Lambracht‐Washington, D., & Rosenberg, R. N. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31428 · Cited by 38 · see citing works

Investigating Interventions in Alzheimer's Disease with Computer Simulation Models

Proctor, C. J., Boche, D., Gray, D. A., & Nicoll, J. A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073631 · Cited by 38 · see citing works

Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds

Joseph‐Mathurin, N., Dorieux, O., Trouche, S. G., Boutajangout, A., Kraska, A., Fontès, P., Verdier, J., Sigurdsson, E. M., Mestre‐Francés, N., & Dhénain, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.013 · Cited by 37 · see citing works

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27 · see citing works

Antibody-based therapies for Huntington’s disease: current status and future directions

Denis, H. L., David, L. S., & Cicchetti, F. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104569 · Cited by 30 · see citing works

Converting maslinic acid into an effective inhibitor of acylcholinesterases

Schwarz, Š., Loesche, A., Lucas, S. D., Sommerwerk, S., Serbian, I., Siewert, B., Pianowski, E., & Csük, R. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.09.007 · Cited by 25 · see citing works

Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders

Liu, L., Ma, D., Zhuo, L., Pang, X., You, J., & Feng, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200606231723 · Cited by 22 · see citing works

Combination Therapy in Alzheimer’s Disease: Is It Time?

Salehipour, A., Bagheri, M., Sabahi, M., Dolatshahi, M., & Boche, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215680 · Cited by 22 · see citing works

Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?

Li, Y., Liu, Y., Wang, Z., & Jiang, Y. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.838555 · Cited by 21 · see citing works

Harnessing the Immune System for Treatment and Detection of Tau Pathology

Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20 · see citing works

Targets, trials and tribulations in Alzheimer therapeutics

Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 18 · see citing works

Effect of amyloid‐β ( A β) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK )‐3β

Amin, J., Paquet, C., Baker, A., Asuni, A. A., Love, S., Holmes, C., Hugon, J., Nicoll, J. A. R., & Boche, D. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12205 · Cited by 19 · see citing works

When Will Alzheimer's Disease be Cured? A Pharmaceutical Perspective

Townsend, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110020 · Cited by 19 · see citing works

Immunomodulation for prion and prion-related diseases

Wısnıewskı, T., & Goñi, F. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.131 · Cited by 19 · see citing works

Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases

Wootla, B., Watzlawik, J. O., Warrington, A. E., Wittenberg, N. J., Đenić, A., Xu, X., Jordan, L. R., Papke, L. M., Zoecklein, L. J., Pierce, M. L., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.2188 · Cited by 18 · see citing works

Potential Roles of Nr4a3-Mediated Inflammation in Immunological and Neurological Diseases

He, S., Jiang, W., Jiang, B., Yu, C., Zhao, G., Li, Y., Qi, L., Zhang, J., & Wang, D. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03945-8 · Cited by 17 · see citing works

Poor Oral Health and Its Neurological Consequences: Mechanisms of Porphyromonas gingivalis Involvement in Cognitive Dysfunction

Olsen, I., & Singhrao, S. K. (2019) · Current Oral Health Reports · doi:10.1007/s40496-019-0212-8 · Cited by 16 · see citing works

Does the Interplay Between Aging and Neuroinflammation Modulate Alzheimer’s Disease Clinical Phenotypes? A Clinico-Pathological Perspective

Taipa, R. J. F., Sousa, A. L., Pires, M. M., & Sousa, N. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160121 · Cited by 14 · see citing works

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?

Kayed, R., Castillo‐Carranza, D. L., & Guerrero‐Munoz, M. J. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s40131 · Cited by 15 · see citing works

Could immunomodulation be used to prevent prion diseases?

Wısnıewskı, T., & Goñi, F. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.177 · Cited by 13 · see citing works

Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?

Matsumoto, Y., & Kohyama, K. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s49923 · Cited by 12 · see citing works

Anti-Amyloid-β Immunotherapy for Alzheimer’s Disease

Crehan, H., & Lemere, C. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00007-1 · Cited by 11 · see citing works

Therapeutic applications of antibodies in non-infectious neurodegenerative diseases

Krishnamurthy, P., & Sigurdsson, E. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.020 · Cited by 8 · see citing works

A New Public Health Paradigm for Alzheimer's Disease Research

Garrett, M. D. (2015) · SOJ Neurology · doi:10.15226/2374-6858/2/2/00117 · Cited by 8 · see citing works

Assessment of the Effects of Altered Amyloid-Beta Clearance on Behavior following Repeat Closed-Head Brain Injury in Amyloid-Beta Precursor Protein Humanized Mice

Maigler, K. C., Buhr, T. J., Park, C. S., Miller, S. A., Kozlowski, D., & Marr, R. (2020) · Journal of Neurotrauma · doi:10.1089/neu.2020.6989 · Cited by 6 · see citing works

Investigating the causal relationship between immune cell and Alzheimer’s disease: a mendelian randomization analysis

Shen, M., Zhang, L., Chen, C., Wei, X., Ma, Y., & Ma, Y. (2024) · BMC Neurology · doi:10.1186/s12883-024-03599-y · Cited by 6 · see citing works

Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes

Mondal, A. C., & Sushma (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666211228100955 · Cited by 4 · see citing works

Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer’s disease

Welikovitch, L. A., Oakley, D. H., Bennett, R. E., Serrano‐Pozo, A., Zhu, H., Ruiz‐Uribe, N. E., Zwang, T. J., Chibnik, L. B., Gómez‐Isla, T., Frosch, M. P., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03037-y · Cited by 4 · see citing works

Multiple Causes of Dementia as Engineered Senescence

Garrett, M. D. (2020) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2020.2.2.227 · Cited by 3 · see citing works

Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer’s Disease

Kazim, S. F., & Iqbal, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00002-8 · Cited by 2 · see citing works

Immunomodulation

Wısnıewskı, T., & Goñi, F. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5338-3_17 · Cited by 1 · see citing works

IMMUNOTHERAPY IN COMBINATION WITH BEHAVIORAL ENRICHMENT IN A CANINE MODEL OF AGING

Davis, P. R. (2014) · UKnowledge (University of Kentucky)

Open questions for Alzheimer's disease

Golde, T. E. (2014)

Immunotherapy for the Treatment of Alzheimer’s Disease

Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00009-4

Screening and evaluation of natural compounds for therapeutic application in Alzheimer's disease

Nirvanashetty, S. (2024) · Swinburne figshare (Swinburne University of Technology) · doi:10.25916/sut.26278636

Developing a Modern Mythology for Alzheimer’s Disease

Garrett, M. D. (2019) · Archives in Neurology & Neuroscience · doi:10.33552/ann.2019.04.000580

Additional file 1 of A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J. M., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M. P., Koyama, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14444875

Additional file 1 of Investigating the causal relationship between immune cell and Alzheimer’s disease: a mendelian randomization analysis

Shen, M., Zhang, L., Chen, C., Wei, X., Ma, Y., & Ma, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26694648

Validation préclinique de l'efficacité de l'ANAVEX2-73 dans des modèles transgénique et non transgénique de la maladie d'Alzheimer

Lahmy, V. (2014) · theses.fr (ABES) · doi:10.70675/23744d67zb26bz4a32zadbfz3931ecca70f5

BindingDB Entry 50047167: Converting maslinic acid into an effective inhibitor of acylcholinesterases.

BindingDB (2017) · UC San Diego · doi:10.7270/q2ws8w46

O3‐07‐08: Aβ42 immunization reduces both tau and Aβ deposits in Alzheimer's disease

Boche, D., Donald, J., Love, S., Neal, J., Holmes, C., & Nicoll, J. A. R. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.2019

Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies

Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116 · see citing works

Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies

Sigurdsson, E. M. (2009) · Current Alzheimer Research · doi:10.2174/156720509789207930 · Cited by 87 · see citing works

THE PROSPECTS FOR A VACCINE FOR ALZHEIMER'S DISEASE

Nicoll, J. A. R. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308883.5

Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works